Matt Posard Joins Vizgen Board of Directors

Single-cell spatial genomics instrument pioneer appoints genomics commercialization expert

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announces the appointment of Matt Posard to their Board of Directors. As the first outside director for Vizgen, Matt will provide guidance to expand market strategies and corporate growth.

A seasoned executive in the genomics and life science space, Matt has an extensive background in launching novel and transformational products, generating high revenue growth, and effectively scaling organizations. Matt held executive positions at Illumina for almost 10 years including global marketing and sales during its first $1B in annual revenue. Matt also served as Senior VP and General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units and was responsible for a notable $100M+ of sales growth in his first year as SVP/GM. Presently, Matt is leading Explore DNA as Founding Principal and serves on many boards for both public and private companies in the life sciences, diagnostics, and therapeutics arena.

“Matt joins our board with an impressive 30 years of commercial and general management expertise in the life sciences industry, combined with a remarkable history of success,” said Terry Lo, President and CEO of Vizgen. “His deep knowledge and background of the genomics market will help advance our mission to bring spatial genomics and our MERSCOPE™ platform to researchers around the world.”

“I am deeply honored to be joining Vizgen’s Board of Directors,” says Matt. “The cutting-edge technology offered by Vizgen’s MERSCOPE platform opens an incredible opportunity within the emerging single-cell spatial genomics market, and I look forward to being a part of it. It’s an exciting time for this highly specialized and accomplished team.”

About MERSCOPE

Vizgen’s MERSCOPE™ platform is the only integrated solution for running MERFISH experiments, and the first complete platform for single-cell spatial genomics. The instrument is flexible and amenable to a large variety of sample or tissue types. It is also accompanied by a custom gene panel design portal, reagents and consumables, an analytical computer, and data visualization software. The MERSCOPE platform offers a user-friendly workflow facilitating each step of a MERFISH experiment, from sample preparation, to measurement, and finally data visualization and analysis. Together these features enable the spatial profiling of hundreds of individual transcripts within hundreds of thousands of cells in a single instrument run.

To learn more about the MERSCOPE platform, please visit: vizgen.com

About Vizgen

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPE™ platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media @Twitter, @LinkedIn and Facebook.